Salvato in:
Dettagli Bibliografici
Autori principali: Yeh, Jih-Chao, Yang, Chin-Hao, Hazam, Prakash Kishore, Selvaraj, Sanjay Prasad, Lin, You-Ying, Hsieh, Chu-Yi, Liou, Je-Wen, Chen, Jyh-Yih
Natura: Artículo científico
Lingua:en
Pubblicazione: European journal of pharmacology 2025
Soggetti:
Accesso online:https://pubmed.ncbi.nlm.nih.gov/40288555/
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1868266211758833665
author Yeh, Jih-Chao
Yang, Chin-Hao
Hazam, Prakash Kishore
Selvaraj, Sanjay Prasad
Lin, You-Ying
Hsieh, Chu-Yi
Liou, Je-Wen
Chen, Jyh-Yih
author_facet Yeh, Jih-Chao
Yang, Chin-Hao
Hazam, Prakash Kishore
Selvaraj, Sanjay Prasad
Lin, You-Ying
Hsieh, Chu-Yi
Liou, Je-Wen
Chen, Jyh-Yih
Yeh, Jih-Chao
Yang, Chin-Hao
Hazam, Prakash Kishore
Selvaraj, Sanjay Prasad
Lin, You-Ying
Hsieh, Chu-Yi
Liou, Je-Wen
Chen, Jyh-Yih
collection PubMed - marine biology
contents Combination of antimicrobial peptide and clinical antibiotic shows enhanced potency toward Acinetobacter baumannii infection. Yeh, Jih-Chao Yang, Chin-Hao Hazam, Prakash Kishore Selvaraj, Sanjay Prasad Lin, You-Ying Hsieh, Chu-Yi Liou, Je-Wen Chen, Jyh-Yih Acinetobacter baumannii Acinetobacter Infections Anti-Bacterial Agents Animals Meropenem Drug Synergism Antimicrobial Peptides Microbial Sensitivity Tests Mice Biofilms Humans Drug Therapy, Combination Male The continued development of novel antimicrobial treatment strategies is crucial for maintaining an effective therapeutic arsenal, and antimicrobial peptides (AMPs) exhibit promising activities against a wide range of pathogens. In this study, we tested the combined effects of an AMP, TP4-3, and meropenem on Acinetobacter baumannii, which is responsible for many severe infections and is associated with high rates of overall mortality and morbidity. This study aimed to develop an effective combination therapy for microbial infections. TP4-3 and meropenem were found to act synergistically toward Acinetobacter baumannii and exhibit an activity profile better than those of the individual compounds. TP4-3 is an antimicrobial peptide with proven activity, low toxicity and extended stability. This AMP was combined with meropenem and tested for efficacy against A. baumannii using a panel of in vitro and in vivo tests. The combination of TP4-3 and meropenem exhibited robust activity against Acinetobacter baumannii pathogens. In particular, the combined treatment demonstrated significant antibiofilm properties and a lower degree of induced resistance than meropenem alone. Additionally, the combination showed an excellent activity profile in in vivo studies. Thus, the combination of TP4-3 and meropenem appears to be an effective strategy to mitigate the detrimental consequences of infections caused by this clinically relevant pathogen. Since the combination of TP4-3 and meropenem displayed better activity than the individual compounds, this strategy of combining AMPs with clinical antibiotics may be suitable for development of clinical treatments targeting various microbial infections.
format Artículo científico
id pubmed_40288555
institution PubMed
language en
publishDate 2025
publisher European journal of pharmacology
record_format pubmed
spellingShingle Combination of antimicrobial peptide and clinical antibiotic shows enhanced potency toward Acinetobacter baumannii infection.
Yeh, Jih-Chao
Yang, Chin-Hao
Hazam, Prakash Kishore
Selvaraj, Sanjay Prasad
Lin, You-Ying
Hsieh, Chu-Yi
Liou, Je-Wen
Chen, Jyh-Yih
Acinetobacter baumannii
Acinetobacter Infections
Anti-Bacterial Agents
Animals
Meropenem
Drug Synergism
Antimicrobial Peptides
Microbial Sensitivity Tests
Mice
Biofilms
Humans
Drug Therapy, Combination
Male
Combination of antimicrobial peptide and clinical antibiotic shows enhanced potency toward Acinetobacter baumannii infection. Yeh, Jih-Chao Yang, Chin-Hao Hazam, Prakash Kishore Selvaraj, Sanjay Prasad Lin, You-Ying Hsieh, Chu-Yi Liou, Je-Wen Chen, Jyh-Yih Acinetobacter baumannii Acinetobacter Infections Anti-Bacterial Agents Animals Meropenem Drug Synergism Antimicrobial Peptides Microbial Sensitivity Tests Mice Biofilms Humans Drug Therapy, Combination Male The continued development of novel antimicrobial treatment strategies is crucial for maintaining an effective therapeutic arsenal, and antimicrobial peptides (AMPs) exhibit promising activities against a wide range of pathogens. In this study, we tested the combined effects of an AMP, TP4-3, and meropenem on Acinetobacter baumannii, which is responsible for many severe infections and is associated with high rates of overall mortality and morbidity. This study aimed to develop an effective combination therapy for microbial infections. TP4-3 and meropenem were found to act synergistically toward Acinetobacter baumannii and exhibit an activity profile better than those of the individual compounds. TP4-3 is an antimicrobial peptide with proven activity, low toxicity and extended stability. This AMP was combined with meropenem and tested for efficacy against A. baumannii using a panel of in vitro and in vivo tests. The combination of TP4-3 and meropenem exhibited robust activity against Acinetobacter baumannii pathogens. In particular, the combined treatment demonstrated significant antibiofilm properties and a lower degree of induced resistance than meropenem alone. Additionally, the combination showed an excellent activity profile in in vivo studies. Thus, the combination of TP4-3 and meropenem appears to be an effective strategy to mitigate the detrimental consequences of infections caused by this clinically relevant pathogen. Since the combination of TP4-3 and meropenem displayed better activity than the individual compounds, this strategy of combining AMPs with clinical antibiotics may be suitable for development of clinical treatments targeting various microbial infections.
title Combination of antimicrobial peptide and clinical antibiotic shows enhanced potency toward Acinetobacter baumannii infection.
topic Acinetobacter baumannii
Acinetobacter Infections
Anti-Bacterial Agents
Animals
Meropenem
Drug Synergism
Antimicrobial Peptides
Microbial Sensitivity Tests
Mice
Biofilms
Humans
Drug Therapy, Combination
Male
url https://pubmed.ncbi.nlm.nih.gov/40288555/